Search - tctmd.com

Displaying 161 - 179 of 179

Sort: Relevancy | Date

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Yael L. Maxwell

January 01, 2014

Presentation

RE-COVER 2: Treatment of Acute VTE with Dabigatran or Warfarin and Pooled Analysis

Presenter: Sam Schulman

December 18, 2013

News Daily News

Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin

Jason Kahn

October 04, 2013

Presentation VEINS 2013

Current Recommendations for VTE Risk Assessment and In-Hospital Prophylaxis

Presenter: Teresa L. Carman

September 21, 2013

Presentation VEINS 2013

Current Recommendations and New Treatment Options for Acute VTE

Presenter: John R. Bartholomew

September 21, 2013

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients

Caitlin E. Cox

September 02, 2013

News Daily News

阿哌沙班在急性静脉血栓栓塞治疗方面不逊色于标准疗法

L.A. McKeown

July 05, 2013

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

L.A. McKeown

July 05, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

Presentation VEINS 2012

VTE and Iliofemoral Occlusions

Presenter: J. Stephen Jenkins

September 15, 2012

Presentation VEINS 2012

Anticoagulants: What is New in VTE

Presenter: John R. Bartholomew

September 14, 2012

News Industry News

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

November 06, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Daily News

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Jason Kahn

February 13, 2011

Video

» Interview

AHA @ TCT Hot-Take Session #2: New World of PE and VTE Management

September 17, 2022

Advertisement

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

RE-COVER 2: Treatment of Acute VTE with Dabigatran or Warfarin and Pooled Analysis

Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin

Current Recommendations for VTE Risk Assessment and In-Hospital Prophylaxis

Current Recommendations and New Treatment Options for Acute VTE

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients

阿哌沙班在急性静脉血栓栓塞治疗方面不逊色于标准疗法

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

VTE and Iliofemoral Occlusions

Anticoagulants: What is New in VTE

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

AHA @ TCT Hot-Take Session #2: New World of PE and VTE Management

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content